Recombinant Human S100P/S100E Protein
SKU: PKSH030800-100
Recombinant Human S100P/S100E Protein
SKU # | PKSH030800 |
Expression Host | E.coli |
Description
Synonyms | MIG9, Protein S100-E, Protein S100-P, S100 Calcium-Binding Protein P, S100E, S100P |
Species | Human |
Expression Host | E.coli |
Sequence | Met 1-Lys 95 |
Accession | P25815 |
Calculated Molecular Weight | 10.4 kDa |
Tag | None |
Bio-activity | Not validated for activity |
Properties
Purity | > 97 % as determined by reducing SDS-PAGE. |
Endotoxin | Please contact us for more information. |
Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
Formulation | Lyophilized from sterile PBS, pH 7.5 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
Reconstitution | Please refer to the printed manual for detailed information. |
Background
Protein S100-P; also known as Protein S100-E; S100 calcium-binding protein P; S100P and S100E; is a nucleus and cytoplasm protein which belongs to theS-100 family. S100P / S100E contains twoEF-hand domains. S100P protein regulates calcium signal transduction and mediates cytoskeletal interaction; protein phosphorylation and transcriptional control. S100P / S100E overexpression can upregulate androgen receptor expression and thereby promote prostate cancer progression by increasing cell growth. S100P / S100E may directly confer resistance to chemotherapy. S100P / S100E induction may be considered an important step in the initial stage of lung adenocarcinomas; whereas its downregulation in advanced stages seems to be important for tumour progression in which DNA methylation and/or feedback transcription processes play a critical role. S100P / S100E plays a major role in the aggressiveness of pancreatic cancer that is likely mediated by its ability to activate RAGE. Interference with S100P / S100E may provide a novel approach for treatment of pancreatic cancer. S100P / S100E could be considered a potential drug target or a chemosensitization target; and could also serve as a biomarker for aggressive; hormone-refractory and metastatic prostate cancer.